Salvage lenalidomide in four rare oncological diseases

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

SZTURZ Petr ADAM Zdeněk REHAK Zdenek KOUKALOVÁ Renata KŘEN Leoš MOULIS Mojmír KREJČÍ Marta MAYER Jiří

Year of publication 2013
Type Article in Periodical
Magazine / Source Tumori
MU Faculty or unit

Faculty of Medicine

Citation
Web http://www.tumorionline.it/articoli.php?archivio=yes&vol_id=1377&id=15326
Doi http://dx.doi.org/10.1700/1377.15326
Field Oncology and hematology
Keywords Langerhans cell histiocytosis; Erdheim-Chester disease; angiomatosis; Castleman disease
Description In rare disorders, there are often no standard therapy recommendations. Patients with refractory disease may require novel experimental approaches. Applied as second- up to fourth-line treatment, lenalidomide (10-25 mg perorally on days 1-21 in a 28-day cycle) was used in our cohort of four adult patients with aggressive, multisystem and relapsing diseases. Complete and long-lasting remissions (more than 1 year, no maintenance therapy) were achieved in patients with Langerhans cell histiocytosis (11 cycles, combination with dexamethasone and etoposide, consolidated by allogeneic blood stem cell transplant) and plasma-cell Castleman disease (15 cycles, monotherapy). Mixed response with complete disappearance of brain infiltrates was reached in Erdheim-Chester disease (6 cycles, monotherapy) and gastrointestinal bleeding was well controlled in multiple angiomatosis (9 cycles, combination with thalidomide). For disease activity evaluation each patient underwent fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography scan imaging, which was complemented by clinical and laboratory investigations.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.